These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 21435189)
1. Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis. Yoo EH; Jang JH; Park KJ; Gwak GY; Kim HJ; Kim SH; Kim DK Int J Lab Hematol; 2011 Oct; 33(5):471-6. PubMed ID: 21435189 [TBL] [Abstract][Full Text] [Related]
2. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation. Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380 [TBL] [Abstract][Full Text] [Related]
3. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. De Stefano V; Fiorini A; Rossi E; Za T; Farina G; Chiusolo P; Sica S; Leone G J Thromb Haemost; 2007 Apr; 5(4):708-14. PubMed ID: 17263783 [TBL] [Abstract][Full Text] [Related]
5. Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation. Bang SM; Lee JS; Ahn JY; Lee JH; Hyun MS; Kim BS; Park MR; Chi HS; Kim HY; Kim HJ; Lee MH; Kim H; Won JH; Yoon HJ; Oh DY; Nam EM; Bae SH; Kim BK; Thromb Haemost; 2009 Mar; 101(3):547-51. PubMed ID: 19277418 [TBL] [Abstract][Full Text] [Related]
6. The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Smalberg JH; Koehler E; Darwish Murad S; Plessier A; Seijo S; Trebicka J; Primignani M; de Maat MP; Garcia-Pagan JC; Valla DC; Janssen HL; Leebeek FW; Blood; 2011 Apr; 117(15):3968-73. PubMed ID: 21364191 [TBL] [Abstract][Full Text] [Related]
7. Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. Poisson J; Plessier A; Kiladjian JJ; Turon F; Cassinat B; Andreoli A; De Raucourt E; Goria O; Zekrini K; Bureau C; Lorre F; Cervantes F; Colomer D; Durand F; Garcia-Pagan JC; Casadevall N; Valla DC; Rautou PE; Marzac C; J Hepatol; 2017 Sep; 67(3):501-507. PubMed ID: 28483676 [TBL] [Abstract][Full Text] [Related]
8. Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis? Lamy M; Palazzo P; Agius P; Chomel JC; Ciron J; Berthomet A; Cantagrel P; Prigent J; Ingrand P; Puyade M; Neau JP Cerebrovasc Dis; 2017; 44(3-4):97-104. PubMed ID: 28609766 [TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis. Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270 [TBL] [Abstract][Full Text] [Related]
10. JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease. Allegra A; Alonci A; Penna G; D'Angelo A; Rizzotti P; Granata A; Musolino C Acta Haematol; 2009; 121(4):218-20. PubMed ID: 19478480 [TBL] [Abstract][Full Text] [Related]
11. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment. De Stefano V; Qi X; Betti S; Rossi E Thromb Haemost; 2016 Jan; 115(2):240-9. PubMed ID: 26333846 [TBL] [Abstract][Full Text] [Related]
12. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. Colaizzo D; Amitrano L; Tiscia GL; Scenna G; Grandone E; Guardascione MA; Brancaccio V; Margaglione M J Thromb Haemost; 2007 Jan; 5(1):55-61. PubMed ID: 17059429 [TBL] [Abstract][Full Text] [Related]
13. Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report. Waiswa M; Seremba E; Ocama P; Ddungu H; Opio K; Okello C; O'shea T; Verhovsek M; Mutyabule R Afr Health Sci; 2014 Dec; 14(4):1069-73. PubMed ID: 25834519 [TBL] [Abstract][Full Text] [Related]
14. Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis. Colaizzo D; Tiscia GL; Bafunno V; Amitrano L; Vergura P; Lupone MR; Grandone E; Guardascione MA; Margaglione M Thromb Res; 2011 Sep; 128(3):233-6. PubMed ID: 21497883 [TBL] [Abstract][Full Text] [Related]
15. The association of the JAK2 46/1 haplotype with non-splanchnic venous thrombosis. Zerjavic K; Zagradisnik B; Lokar L; Krasevac MG; Vokac NK Thromb Res; 2013 Aug; 132(2):e86-93. PubMed ID: 23845539 [TBL] [Abstract][Full Text] [Related]
16. Sassi H; Menif S; Ammar SB; Farrah A; Othmen HBH; Amouri H Pan Afr Med J; 2021; 39():194. PubMed ID: 34603575 [TBL] [Abstract][Full Text] [Related]
17. [JAK2 V617F and exon 12 genetic variations in Korean patients with BCR/ABL1-negative myeloproliferative neoplasms]. Kim JT; Cho YG; Choi SI; Lee YJ; Kim HR; Jang SJ; Moon DS; Park YJ; Park G Korean J Lab Med; 2010 Dec; 30(6):567-74. PubMed ID: 21157140 [TBL] [Abstract][Full Text] [Related]
18. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms. Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412 [TBL] [Abstract][Full Text] [Related]